Pneumococcal conjugate vaccine rollout in India: Expectations and challenges
Rosemol Varghese, Balaji Veeraraghavan, Yuvraj Jeyaraman, Girish Kumar, Narendra Kumar Arora, S BalasubramanianIndian Journal of Medical Microbiology 2019 37(2):141-146 India is one among the four Asian countries with the greatest number of deaths due to pneumococcal infection among children under 5 years. pneumococcal conjugate vaccine (PCV) has been introduced in a phased manner in five major Indian states. Ambiguity remains in choosing the appropriate type of PCV and optimum schedule with maximum effectiveness specific for each country. Here, we discuss the evidences with respect to serotype coverage, immunogenicity, reactogenicity and dosage schedule for introduction of PCV13 in India. In addition, the expected PCV impact and the challenges are detailed. PCV13 is expected to provide >75% serotype coverage for invasive pneumococcal disease (IPD) serotypes in Indian children combined with the replacement by nonvaccine serotypes which is unpredictable due to lack of complete data. Nasopharyngeal (NP) surveillance is easy, feasible and can replace IPD surveillance in resource-poor settings. Continuous IPD as well as NP surveillance in all the regions are necessary to assess the impact of PCV in India.
Review recent changes in ACIP's recommendations for pneumococcal conjugate vaccine use in older adults.Morbidity &Mortality Weekly Report
AbstractObjectivesPneumococcal and influenza vaccination rates have been suboptimal in studies of immunosuppressed patients. We aimed to assess barriers to and increase rates of 23-valent pneumococcal polysaccharide vaccine (PPSV23) and influenza vaccination in this group. The primary endpoint was a statistically significant increase in adequate PPSV23 and influenza vaccination.MethodsIn 2017, rheumatology outpatients completed an anonymous questionnaire recording vaccination knowledge, status, and barriers. Simultaneously, a low-cost multifaceted quality improvement (QI) intervention was performed. All outpatients on oral...
Abstract Serogroup 6 remains common in the pneumococcal-conjugated vaccine era in Bulgaria; therefore, we investigated its clonal and serotype dynamics. The antibiotic susceptibilities were assessed by broth microdilution. Strains identified as serogroup 6 with latex agglutination method were subjected to serotype-specific PCRs. Erythromycin-resistant strains were analyzed by PCR for presence of ermB and mefE genes. MLST was performed to define clonal composition of the sequence types (STs). Serogroup 6 was represented by 40 (13.3%) from 301 invasive and non-invasive Streptococcus pneumoniae isolates. Molecular se...
In November 2011, Malawi introduced the 13-valent pneumococcal conjugate vaccine (PCV13) into the routine infant schedule. Four to 7 years after introduction (2015 –2018), rolling prospective nasopharyngeal car...
[MSF] New Delhi/New York -Gavi, the Vaccine Alliance should immediately stop giving millions of dollars in financial incentives to pharmaceutical companies Pfizer and GlaxoSmithKline (GSK) for the pneumococcal conjugate vaccine (PCV), said the international humanitarian organization Doctors Without Borders/M édecins Sans Frontières (MSF) ahead of the group's board meeting in New Delhi, India on December 4 and 5. Instead, Gavi should use the remaining US $262 million of the US $1.5 billion subsidy fund to support the ro
Condition: Pneumococcal Infections Intervention: Biological: 13-valent pneumococcal conjugate vaccine Sponsors: Telethon Kids Institute; Papua New Guinea Institute of Medical Research Completed
Conclusion: According to WHO-recommended thresholds for interpreting cost-effectiveness, introduction of PCV-13 for children under 5 years in the Islamic Republic of Iran would be cost-effective. PMID: 31774134 [PubMed - in process]